Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin

NCT06677190 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06677190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
December 20, 2024
Completion date
June 30, 2029
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, gynecologic cancer, ovarian cancer, ovarian carcinoma, uterine cancer, vaginal cancer, vulvar cancer